AbbVie, building out its post-Humira future, posts 5 late-stage trial wins for Skyrizi and Rinvoq

As AbbVie comes under renewed scrutiny for its pricing and patenting strategies, the company is still working to build out the case for its next-gen immunology drugs Skyrizi and Rinvoq.

In Crohn's disease, Skyrizi beat placebo in two separate phase 3 studies examining different dosages in adults with moderate to severe disease who have had various prior treatments. The trials met their co-primary endpoints of clinical remission and endoscopic response after 12 weeks.